Brief: Resverlogix reports $87 mln private placement with Shenzhen Hepalink

Shenzhen Hepalink Pharmaceutical Co

13/10/2017 14:27

Oct 13 (Reuters) - Resverlogix Corp  RVX.TO : 
    * Resverlogix announces $87 million private placement with 
shenzhen hepalink 
    * Resverlogix Corp - net proceeds of offering will 
primarily be used to repay company's $68.8 million secured loan 
which matures on December 26, 2017 
    * Resverlogix Corp -  private placement of 60.4 million 
equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. At a 
price of $1.44 per unit 
    * Resverlogix-Proceeds will also be used to fund 
research,development activities for clinical trial activities 
related to phase 3 betonmace trial 
    * Resverlogix -  placement to address co's financial 
difficulties by providing sufficient funds to repay loan and to 
satisfy  short term cash requirements 
 
Source text for Eikon:  ID:nGNXOEXFSa  
Further company coverage:  RVX.TO  
 
 ((bangalore.newsroom@thomsonreuters.com;))